SEC Form 4 · accession 0000899243-18-026655
Unity Biotechnology, Inc. · UBX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
II Robert C. Goeltz
Officer — Chief Financial Officer
Period of report
Oct 10, 2018
Accepted (ET)
Oct 12, 2018 · 5:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001463361
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | Oct 10, 2018 | M | 5,000 | $3.43 | A | 101,348 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.43 | Oct 10, 2018 | M | 5,000 | D | — | Sep 26, 2027 | Common Stock | 5,000 | 120,620 | D |
Explanation of responses
- F1The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on September 5, 2018 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.